Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis.
BACKGROUND
As psoriasis patients often require continuous treatment optimal therapy has to provide efficacy and a good safety profile over the long term.


OBJECTIVE
The aim of this multicentre study was to assess the efficacy, safety and tolerability of tacalcitol (4 microg g(-1)) ointment (Curatoderm, Hermal, Reinbek, Germany) applied once daily over a treatment period of 18 months.


METHODS
Efficacy parameters were Psoriasis Area Severity Index (PASI), based on summed scores of erythema, infiltration and scaling and total body surface involvement (TBI). Safety assessment included serum levels of calcium, parathyroid hormone, calcitonin, 1,25-dihydroxy vitamin D3 (calcitriol); urinary calcium, creatinine, calcium/creatinine ratio in spot and 24-h urine and urinary alpha(1)-microglobulin. A group of 304 patients with chronic plaque psoriasis, covering between 7% and 20% of the body surface area was included for the initial treatment phase of 3 months. Of the 257 patients who completed the initial 3 months, 197 patients continued in a second treatment phase of 15 months.


RESULTS
Tacalcitol treatment proved to be effective in reducing the severity of psoriasis and maintained therapeutic response over the study period. The median PASI fell from 9.5 to 4 .6 at month 3 and to 3.25 at month 18 (P < 0.0001). The median improvement in TBI was 30% at month 3 and 50% at month 18. In no patient was there any relevant disturbance of calcium homeostasis. There were no significant changes in mean values of serum calcium, parathyroid hormone and calcitriol. Additionally no significant changes in 24-h urinary excretion evaluation were observed. There was no correlation between levels of serum calcium or urinary calcium and amount of tacalcitol ointment used, even in the patients requiring the largest amounts of ointment (up to 13 g day(-1) and up to 20% of body area affected). Treatment was generally well tolerated and there were no serious or unexpected adverse events reported. However, discontinuation of treatment as a result of skin irritation was seen in 5.9% of patients. The greatest frequency of cutaneous side-effects occurred during initial treatment and the incidence decreased markedly as the treatment was well-tolerated with continued use.


CONCLUSIONS
Tacalcitol ointment once daily was demonstrated to be efficacious, safe and well tolerated in the long-term control of plaque psoriasis in patients with up to 20% body surface involvement.
van de Kerkhof
P C M
PC
Department of Dermatology, University Hospital Nijmegen, PO Box 9101, NL-6500 HB Nijmegen, The Netherlands. P.vanderKerkhof@derma.azu.nl
Berth-Jones
J
J
Griffiths
C E M
CE
Harrison
P V
PV
Hönigsmann
H
H
Marks
R
R
Roelandts
R
R
Schöpf
E
E
Trompke
C
C
D000293:Adolescent; D000328:Adult; D000368:Aged; D002116:Calcitonin / Q000097:blood; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000378:metabolism; D002908:Chronic Disease; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004100:Dihydroxycholecalciferols / Q000009:adverse effects / Q000627:therapeutic use*; D004890:Erythema / Q000139:chemically induced; D005260:Female; D006706:Homeostasis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D010281:Parathyroid Hormone / Q000097:blood; D011446:Prospective Studies; D011565:Psoriasis / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D013997:Time Factors
D003879:Dermatologic Agents; D004100:Dihydroxycholecalciferols; D009824:Ointments; D010281:Parathyroid Hormone; C023850:1 alpha,24-dihydroxyvitamin D3; D002116:Calcitonin; D002117:Calcitriol; D002118:Calcium